Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Prialt Sales Sluggish, But Elan Expects Rapid Growth

This article was originally published in The Pink Sheet Daily

Executive Summary

Additional audiences for the pain product are being targeted following a "quiet" launch at the beginning of the year.

You may also be interested in...



Merck Signs On For Neuromed’s Chronic Pain Agent

Merck could pay up to $450 mil. for the class of oral N-type calcium channel blockers.

Merck Signs On For Neuromed’s Chronic Pain Agent

Merck could pay up to $450 mil. for the class of oral N-type calcium channel blockers.

Elan Maxipime Shortage Due To Manufacturing Suspension

Maxipime manufacturer Bristol-Myers Squibb says it temporarily stopped manufacturing cefepime in January due to documentation issues related to bulk manufacturing. FDA accepts Bristol request to release additional product under an amended filing April 12, Bristol says.

Topics

UsernamePublicRestriction

Register

PS062650

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel